Angelini Ventures
Developer of biotechnological solutions designed to create therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies. The company specializes in highly selective compounds that modulate sodium channels that result in treatment resistance in certain rare genetic epilepsies, enabling medical professionals to develop effective therapies for these patients' medical needs.